8.12.2024 EO-3021 Elicits Responses in Advanced CLDN18.2+ Gastric/GEJ Cancer

Treatment with EO-3021 (SYSA1801) produced promising preliminary data in a small cohort of patients with advanced, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) cancers expressing Claudin 18.2 (CLDN18.2), according to dose-escalation findings from a phase 1 trial (NCT05980416).1

Among 15 patients with evaluable gastric or GEJ cancers, 7 (47%) had CLDN18.2 expression in at least 20% of tumor cells at a data cutoff date of June 10, 2024